High growth potential neoSurgical is a commercial-stage medical devices company with a focused product pipeline headed by neoClose for Lap surgery port site closure, presenting a potential $300 million market opportunity and room for expansion in global markets such as the U.S. and Europe.

Strategic expansion With a recently approved product in key markets and a lean organization (fewer than 50 employees), there is an opportunity to partner or co-sell with larger distributors or target teaching hospitals to accelerate adoption and scale sales efficiently.

Early-stage revenue Current revenue is below one million dollars, indicating a need for targeted customer acquisition strategies, clinical validation storytelling, and early adoptor programs to unlock bigger multi-year contracts and upsell adjacent surgical closure solutions.

Competitive positioning neoClose is positioned as a potential new standard in laparoscopy port site closure, which can be highlighted in competitive differentiators against other surgical closure devices and integrated into procurement conversations with hospital procurement and surgical leadership.

Technology leverage The tech stack and digital presence (React, analytics, modern web tools) can support targeted marketing, demand generation, and digital onboarding for surgeons, enabling scalable outreach, case studies, and online education to drive adoption.